Navigation Links
First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval
Date:7/22/2008

ditional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

(1) Avastin(TM), a registered trademark of Genentech, Inc.

(2) Field RW, Smith BJ, Platz CE, Robinson RA, Neuberger JS, Brus CP, et al. Lung cancer histologic type in the Surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004;96:1105--7

(3) Andreas Stang ,Hermann Pohlabeln , Klaus M.Muller ,Ingeborg Jahn , Klaus Giersiepen, Karl-Heinz Jockel Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer (2006) 52 ,29 --36

Contact:

Media& Investors

Ron Kamienchick

T: +1-646- 509 1893

E: investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... 9 Avinger, Inc., a medical device company ... combat peripheral artery disease, announces the enrollment of ... OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial. ... study intended to evaluate the Wildcat Catheter,s ability ...
... (Nasdaq: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and mediated diseases, today announced ... fiscal quarter and fiscal year ended June 30, 2010 ... 2010.  The company will conduct a conference call and ...
Cached Medicine Technology:First Patient Enrolled in 'CONNECT' Clinical Trial 2Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference 2
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... An article in Fortune on Monday, ... critical to organizations that deal with PCI (Payment Card ... data security, is worsening . Using numbers from ... major category out of the twelve measured improved, barring ... the craziness that has gone on in the retail ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
Breaking Medicine News(10 mins):Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3
... Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned ... that RLL has received approval from the U.S. ... Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) ... for the drug was submitted by Ranbaxy, from ...
... published in the Spring 2009 edition of Multiple ... Spinal Association ( www.UnitedSpinal.org ) and the North American ... importance of understanding the biological onset of Multiple Sclerosis ... greater understanding and treatment of MS in adults. The ...
... Two new Directors join the Board of the ... (Infectious Disease Research Institute) announced today that Dr. ... President (SVP) Scientific Affairs to assist the organization ... programs. Dr. Auditore-Hargreaves has a proven track record ...
... Hurricane Ike during a free public forum at Rice University ... Ed Emmett will discuss the leadership challenges they had to ... Guiding Houston through the Storm" will be held from 6 ... Rice campus, 6100 Main St. , In conjunction with ...
... Sick or injured African-American patients wait about ... before being transferred to an inpatient hospital bed ... national study published in the journal Academic ... underscore the urgency to find equitable, cost-effective solutions ...
... children and adolescents, with the active involvement of their ... the Seven Steps to Success described in the current ... published by Mary Ann Liebert, Inc. The article is ... A team of experts that includes physicians and psychologists ...
Cached Medicine News:Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:United Spinal Association Report Reveals the Importance of Studying Multiple Sclerosis in Children: Developing New Insights into MS in Adults 2Health News:IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs 2Health News:IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs 3Health News:Public forum at Rice with mayor and county judge marks 6-month Ike anniversary 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 3Health News:7 steps to successful child and adolescent weight loss 2
Offers the dual convenience of resecting tissue while simultaneously evacuating through a suction channel in the instrument....
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
The most traditional style of instrument, a classical punch shape with the parrot beak upper jaw to aid in the capture of tissue....
This family of punches offers the best of both worlds the lowest profile and the largest bite, facilitating end-on and lateral cutting the most versatile instrument available....
Medicine Products: